Predictive in vivo animal models and translation to clinical trials

Drug Discovery Today

Volumn 17, Issue 5-6, 2012, Pages 253-260

  Cook, Natalie ^a,b   Jodrell, Duncan I ^a,b   Tuveson, David A ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SUNITINIB; VASCULOTROPIN INHIBITOR;

BREAST CANCER; CANCER GRAFT; CANCER MODEL; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HUMAN; IN VIVO STUDY; ISOGRAFT; LUNG CANCER; LYMPHOMA; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PREDICTIVE VALUE; REVIEW; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS;

EID: 84857995039     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.003     Document Type: Review

References (71)

1. J.I. Johnson Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br. J. Cancer 84 2001 1424 1431
2. M. Suggitt, and M.C. Bibby 50 years of preclinical anticancer drug screening: empirical to target-driven approaches Clin. Cancer Res. 11 2005 971 981
3. K.K. Frese, and D.A. Tuveson Maximizing mouse cancer models Nat. Rev. Cancer 7 2007 645 658
4. J. Jonkers, and A. Berns Conditional mouse models of sporadic cancer Nat. Rev. Cancer 2 2002 251 265
5. A. Ocana Preclinical development of molecular-targeted agents for cancer Nat. Rev. Clin. Oncol. 8 2010 200 209
6. B.A. Teicher Tumor models for efficacy determination Mol. Cancer Ther. 5 2006 2435 2443
7. N.E. Sharpless, and R.A. Depinho The mighty mouse: genetically engineered mouse models in cancer drug development Nat. Rev. Drug Discov. 5 2006 741 754
8. J.K. Peterson, and P.J. Houghton Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development Eur. J. Cancer 40 2004 837 844
9. S.f.C.T.B.o. Directors The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients Clin. Trials 3 2006 154 157
10. K.P. Olive, and M.A. Jacobetz Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
11. N. Cook K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses Methods Enzymol. 439 2008 73 85
12. O.J. Becher, and E.C. Holland Genetically engineered models have advantages over xenografts for preclinical studies Cancer Res. 66 2006 3355 3358 discussion 3358-3359
13. T. Voskoglou-Nomikos Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin. Cancer Res. 9 2003 4227 4239
14. M.C. Bibby Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages Eur. J. Cancer 40 2004 852 857
15. R.M. Hoffman Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic Invest. New Drugs 17 1999 343 359
16. I.J. Fidler, and L.M. Ellis The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 79 1994 185 188
17. T. Kubota Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation J. Cell Biochem. 56 1994 4 8
18. K. Garber From human to mouse and back: 'tumorgraft' models surge in popularity J. Natl Cancer Inst. 101 2009 6 8
19. X. Dong Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy Clin. Cancer Res. 16 2010 1442 1451
20. M. Hidalgo A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer Mol. Cancer Ther. 10 2011 1311 1316
21. T. Van Dyke, and T. Jacks Cancer modeling in the modern era: progress and challenges Cell 108 2002 135 144
22. O. Casanovas Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
23. K.P. Olive, and D.A. Tuveson The use of targeted mouse models for preclinical testing of novel cancer therapeutics Clin. Cancer Res. 12 2006 5277 5287
24. M. Singh Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models Nat. Biotechnol. 28 2010 585 593
25. S.R. Hingorani Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
26. D. Dankort Braf(V600E) cooperates with Pten loss to induce metastatic melanoma Nat. Genet. 41 2009 544 552
27. T.G. Roberts Jr. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials JAMA 292 2004 2130 2140
28. D.J. Slamon Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
29. G.D. Demetri Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
30. T.A. Yap Envisioning the future of early anticancer drug development Nat. Rev. Cancer 10 2010 514 523
31. C.P. Carden Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov. Today 15 2009 88 97
32. J. Heyer Non-germline genetically engineered mouse models for translational cancer research Nat. Rev. Cancer 10 2010 470 480
33. K. Brindle New approaches for imaging tumour responses to treatment Nat. Rev. Cancer 8 2008 94 107
34. M.E. Seaman Molecular imaging agents: impact on diagnosis and therapeutics in oncology Expert Rev. Mol. Med. 12 2010 E20
35. G. Francia Mouse models of advanced spontaneous metastasis for experimental therapeutics Nat. Rev. Cancer 11 2011 135 141
36. A.D. Rhim EMT and dissemination precede pancreatic tumor formation Cell 148 2012 349 361
37. H. Haeno Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies Cell 148 2012 362 375
38. D.A. Tuveson, and J.P. Neoptolemos Understanding metastasis in pancreatic cancer: a call for new clinical approaches Cell 148 2012 21 23
39. C. Zhou Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol. 12 2011 735 742
40. K. Politi Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors Genes Dev. 20 2006 1496 1510
41. H. Ji The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell 9 2006 485 495
42. T. De Raedt Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors Cancer Cell 20 2011 400 413
43. V. Lallemand-Breitenbach Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia J. Exp. Med. 189 1999 1043 1052
44. P.P. Pandolfi APL as a paradigm in biomedical research: a journey toward the cure Curr. Top. Microbiol. Immunol. 313 2007 1 2
45. K. Pietras, and D. Hanahan A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23 2005 939 952
46. M. Paez-Ribes Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
47. C.W. Chiu Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis J. Clin. Oncol. 28 2010 4425 4433
48. J.C. Yao Everolimus for advanced pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 514 523
49. E. Raymond Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 501 513
50. G.L. James Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells Science 260 1993 1937 1942
51. N.E. Kohl Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat. Med. 1 1995 792 797
52. S.J. Cohen Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma J. Clin. Oncol. 21 2003 1301 1306
53. A.D. Cox, and C.J. Der Ras history: the saga continues Small Gtpases 1 2011 2 27
54. S.R. Hingorani Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice Cancer Cell 7 2005 469 483
55. S. Rottenberg Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer Proc. Natl. Acad. Sci. U.S.A. 104 2007 12117 12122
56. A.J. Murgo Designing phase 0 cancer clinical trials Clin. Cancer Res. 14 2008 3675 3682
57. X. Liu Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer Proc. Natl Acad. Sci. U.S.A. 104 2007 12111 12116
58. T.A. Stewart Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes Cell 38 1984 627 637
59. E. Sinn Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo Cell 49 1987 465 475
60. S. Rottenberg High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc. Natl Acad. Sci. U.S.A. 105 2008 17079 17084
61. T. Hay Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin Cancer Res. 69 2009 3850 3855
62. D.J. Bearss Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors Oncogene 19 2000 1114 1122
63. E.L. Jackson The differential effects of mutant p53 alleles on advanced murine lung cancer Cancer Res. 65 2005 10280 10288
64. J.A. Engelman Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat. Med. 14 2008 1351 1356
65. A.C. Faber Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc. Natl. Acad. Sci. U.S.A. 106 2009 19503 19508
66. S. Koschmieder Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis Blood 105 2005 324 334
67. Y. Hu Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Phi leukemia in mice Proc. Natl. Acad. Sci. U.S.A. 103 2006 16870 16875
68. J.M. Adams The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 318 1985 533 538
69. C.A. Schmitt Genetic analysis of chemoresistance in primary murine lymphomas Nat. Med. 6 2000 1029 1035
70. E.M. Rego Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha Oncogene 25 2006 1974 1979
71. E.M. Rego Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins Proc. Natl. Acad. Sci. U.S.A. 97 2000 10173 10178